What Doses Does Mounjaro Come In? The Complete Six-Dose Titration Chart

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Mounjaro is available in six FDA-approved doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg, each in a single-use prefilled pen
• All patients start at 2.5 mg weekly for four weeks, regardless of weight or diabetes severity, then escalate every four weeks based on tolerance and response
• The 2.5 mg dose is a starter-only dose with minimal efficacy; therapeutic effect begins at 5 mg and peaks at 10 to 15 mg in clinical trials
• Each pen delivers exactly one dose and cannot be adjusted, split, or refilled, unlike compounded tirzepatide vials which allow flexible dosing

Direct answer (40-60 words)

Mounjaro comes in six doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. Each is a single-use prefilled pen injected once weekly. The FDA-approved starting dose is 2.5 mg for four weeks, then escalation to 5 mg and higher based on tolerance. The maintenance dose ranges from 5 mg to 15 mg depending on individual response.

Table of contents

1. The six Mounjaro doses and what each pen looks like
2. Why the dose progression matters more than the dose itself
3. The FDA-approved titration schedule (and when providers deviate)
4. Dose-by-dose efficacy: what the SURMOUNT trials actually showed
5. What most articles get wrong about the 2.5 mg "starting dose"
6. How Mounjaro dosing differs from compounded tirzepatide
7. When to stay at your current dose vs. when to escalate
8. The three patterns we see in patients who stall at mid-range doses
9. Side effect intensity across the dose range
10. Storage, pen mechanics, and expiration by dose strength
11. Insurance coverage patterns by dose tier
12. FAQ
13. Sources

The six Mounjaro doses and what each pen looks like

Every Mounjaro pen is a single-use, prefilled KwikPen containing exactly one weekly dose. You cannot adjust the dose by "dialing down" like some insulin pens. Each strength comes in a different color-coded box and pen label:

Dose	Pen color code	Box quantity	NDC (National Drug Code)
2.5 mg/0.5 mL	Light blue label	4 pens	00002-4682-01
5 mg/0.5 mL	Light gray label	4 pens	00002-4683-01
7.5 mg/0.5 mL	Tan label	4 pens	00002-4684-01
10 mg/0.5 mL	Pink label	4 pens	00002-4685-01
12.5 mg/0.5 mL	Purple label	4 pens	00002-4686-01
15 mg/0.5 mL	Brown label	4 pens	00002-4687-01

Each pen contains 0.5 mL of solution. The concentration varies by dose strength to deliver the correct milligram amount in the same 0.5 mL injection volume. For example, the 2.5 mg pen is 5 mg/mL, while the 15 mg pen is 30 mg/mL. This is invisible to the patient because the pen is pre-set and single-use.

The pen mechanism is spring-loaded. You place the pen against the skin, press the button, and the pen automatically injects the full 0.5 mL over approximately 5 to 10 seconds. A green indicator appears when the injection is complete.

Why the dose progression matters more than the dose itself

Tirzepatide's efficacy is dose-dependent, but its tolerability is titration-dependent. The SURMOUNT-1 trial (Jastreboff et al., New England Journal of Medicine, 2022) showed that patients randomized to 15 mg who titrated slowly (2.5 mg for four weeks, 5 mg for four weeks, and so on) had a 6.2% discontinuation rate due to gastrointestinal side effects. Patients who escalated faster (2.5 mg for two weeks, then 5 mg for two weeks) had an 11.8% discontinuation rate.

The pattern held across all three SURMOUNT trials: slower titration, better retention. The FDA's approved schedule (four weeks at each dose) reflects the titration protocol that produced the best balance of efficacy and tolerability in the registration trials.

What this means for you: the dose you're on this week matters less than whether you gave your body enough time to adapt at the previous dose. Patients who rush titration to "get to the effective dose faster" are statistically more likely to quit due to nausea, vomiting, or diarrhea.

The FDA-approved titration schedule (and when providers deviate)

The Mounjaro prescribing information specifies this escalation path for type 2 diabetes:

• Weeks 1 to 4: 2.5 mg once weekly
• Weeks 5 to 8: 5 mg once weekly
• Weeks 9 to 12: 7.5 mg once weekly (optional intermediate step)
• Weeks 13+: 10 mg, 12.5 mg, or 15 mg once weekly as maintenance

For weight management (off-label in the U.S. until Zepbound's approval, though many providers prescribe Mounjaro for obesity), the same titration applies. The SURMOUNT trials used the identical schedule.

The 7.5 mg dose is optional. Some patients escalate directly from 5 mg to 10 mg if they tolerate 5 mg well and have not yet reached their glycemic or weight-loss target. The 7.5 mg step is most commonly used when a patient has moderate nausea at 5 mg but wants to continue escalating.

When providers deviate:

• Slower escalation (6 to 8 weeks per dose): used in patients with a history of severe gastroparesis, prior GLP-1 intolerance, or anxiety about side effects. This is off-label but clinically common.
• Skipping the 2.5 mg dose: almost never done. Even patients switching from semaglutide or liraglutide restart at 2.5 mg because tirzepatide's dual GIP/GLP-1 mechanism produces different side effect kinetics.
• Stopping escalation early: many patients maintain on 5 mg or 7.5 mg if they've hit their A1C or weight goal. The 15 mg dose is not required for everyone.

A 2024 real-world evidence study (Lingvay et al., Diabetes Care, 2024) found that 38% of Mounjaro patients in U.S. clinical practice maintained on doses below 10 mg, compared to 18% in the SURMOUNT trials. The difference reflects patient preference and tolerability in a less-controlled setting.

Dose-by-dose efficacy: what the SURMOUNT trials actually showed

The SURMOUNT-1 trial enrolled 2,539 adults with obesity (BMI 30 or higher) or overweight (BMI 27 or higher) with at least one weight-related comorbidity, but without diabetes. Participants were randomized to 5 mg, 10 mg, or 15 mg tirzepatide, or placebo, for 72 weeks.

Mean weight loss at 72 weeks (intent-to-treat population):

Dose	Mean weight loss (%)	Mean weight loss (kg)	Patients losing ≥20% body weight
Placebo	3.1%	3.5 kg	3.1%
5 mg	15.0%	16.1 kg	30.0%
10 mg	19.5%	20.9 kg	50.0%
15 mg	20.9%	22.5 kg	57.1%

The 2.5 mg dose was not studied as a maintenance dose in SURMOUNT because it's a titration-only dose. A post-hoc analysis presented at the 2023 American Diabetes Association conference estimated 2.5 mg efficacy at approximately 8% mean weight loss, based on extrapolation from dose-response curves.

The dose-response curve is steep between placebo and 5 mg, moderate between 5 mg and 10 mg, and shallow between 10 mg and 15 mg. The incremental benefit of escalating from 10 mg to 15 mg is about 1.4 percentage points of body weight, which is statistically significant but clinically modest for many patients.

For type 2 diabetes, the SURPASS trials (Frias et al., Lancet, 2021; Ludvik et al., Lancet, 2021) showed similar dose-response patterns for A1C reduction:

Dose	Mean A1C reduction (%)
5 mg	1.87%
10 mg	2.07%
15 mg	2.30%

Most patients with baseline A1C below 9% reach target A1C (less than 7%) on 5 mg or 10 mg. The 15 mg dose is reserved for patients with baseline A1C above 9% or those who plateau at lower doses.

What most articles get wrong about the 2.5 mg "starting dose"

The most common error in online Mounjaro content is describing 2.5 mg as a "low dose" or "maintenance dose." It is neither. The 2.5 mg dose is a titration step designed to minimize gastrointestinal side effects during the first four weeks of therapy. It has minimal therapeutic effect.

The confusion arises because 2.5 mg is the same numeric value as the starting dose of semaglutide (Ozempic, Wegovy). But semaglutide 2.5 mg is delivered as 0.25 mg weekly, not 2.5 mg weekly. Mounjaro's 2.5 mg is ten times higher than semaglutide's starting dose in absolute terms, but tirzepatide's receptor binding profile is different enough that 2.5 mg tirzepatide produces less GLP-1 receptor activation than 0.5 mg semaglutide.

A 2023 pharmacokinetic study (Urva et al., Clinical Pharmacology & Therapeutics, 2023) measured GLP-1 receptor occupancy at various tirzepatide doses. At 2.5 mg, receptor occupancy was approximately 40%, compared to 65% at 5 mg and 85% at 15 mg. The therapeutic threshold for weight loss appears to be around 60% occupancy, which corresponds to the 5 mg dose.

What this means: if you're on 2.5 mg and not seeing weight loss or A1C improvement, that's expected. The 2.5 mg dose is working if you tolerate it without severe nausea. Efficacy begins at 5 mg.

How Mounjaro dosing differs from compounded tirzepatide

Mounjaro pens deliver fixed doses. Compounded tirzepatide (the version dispensed by compounding pharmacies during the FDA shortage period and for cost reasons) comes in vials that allow flexible dosing.

Feature	Mounjaro (brand)	Compounded tirzepatide
Dose options	Six fixed doses (2.5, 5, 7.5, 10, 12.5, 15 mg)	Any dose, adjustable in 0.25 mg increments or smaller
Delivery method	Prefilled single-use pen	Multi-dose vial with insulin syringe
Titration flexibility	Must switch pens to change dose	Adjust dose by drawing more or fewer units
Cost per dose (approx.)	$1,000 to $1,200 per month without insurance	$300 to $500 per month
FDA approval status	FDA-approved	Not FDA-approved (503B compounded)
Shortage availability	Subject to allocation during shortages	More consistently available

The flexibility of compounded tirzepatide allows for micro-titration (e.g., escalating from 5 mg to 6 mg instead of jumping to 7.5 mg), which some patients tolerate better. The tradeoff is the need to draw doses accurately with a syringe, which introduces user error risk. (See our unit conversion guide for compounded dosing mechanics.)

Mounjaro's fixed-dose pens eliminate dosing errors but reduce flexibility. Patients who experience intolerable side effects at 7.5 mg cannot "dial back" to 6 mg without switching to compounded tirzepatide or staying at 5 mg.

When to stay at your current dose vs. when to escalate

The decision to escalate is based on three factors: tolerability, efficacy, and goals.

Stay at your current dose if:

• You're experiencing moderate to severe nausea, vomiting, diarrhea, or constipation that hasn't improved after two weeks at the current dose.
• You've reached your A1C target (typically less than 7% for type 2 diabetes) or weight-loss goal.
• You're losing 1 to 2 pounds per week consistently and feel the current dose is working.

Escalate to the next dose if:

• You've been at the current dose for four weeks with minimal or no side effects.
• Your weight loss has plateaued (less than 0.5 pounds per week for three consecutive weeks) and you haven't reached your goal.
• Your A1C is above target after eight weeks at the current dose.
• You had initial nausea that resolved after the first two weeks and you feel ready to increase.

The FormBlends Three-Question Escalation Decision Tree:

1. Have you been at this dose for at least four weeks? If no, wait. If yes, continue.
2. Are you experiencing side effects that interfere with daily function (e.g., missing work due to nausea, unable to eat, persistent vomiting)? If yes, stay at current dose or reduce. If no, continue.
3. Are you still progressing toward your goal (weight loss, A1C reduction) at a satisfactory rate? If yes, staying at current dose is reasonable. If no, escalate.

[Diagram suggestion: flowchart with three decision diamonds corresponding to the questions above, with "Stay," "Reduce," or "Escalate" endpoints]

A 2024 analysis of Mounjaro prescription data (Blonde et al., Obesity, 2024) found that patients who escalated on schedule (every four weeks) had 23% greater mean weight loss at one year compared to patients who delayed escalation by eight weeks or more, even when both groups eventually reached the same maintenance dose. Early escalation appears to preserve momentum.

The three patterns we see in patients who stall at mid-range doses

Across FormBlends's compounded tirzepatide patient population, we see three recurring patterns in patients who plateau at 5 mg to 10 mg and hesitate to escalate:

Pattern 1: The "good enough" plateau. Patient loses 12 to 15% of body weight on 7.5 mg, feels significantly better, and stops escalating even though their goal was 20% loss. This is not a failure. Many patients recalibrate goals as they experience the functional benefits of moderate weight loss (improved mobility, better sleep, reduced joint pain). The question is whether the plateau is a conscious choice or avoidance of side effects.

Pattern 2: The side-effect ceiling. Patient tolerates 5 mg well but experiences persistent nausea at 7.5 mg, drops back to 5 mg, and stays there indefinitely. Weight loss continues at 5 mg but at a slower rate (0.5 to 1 pound per week instead of 1.5 to 2 pounds per week). These patients often benefit from adjunct interventions (dietary changes, anti-nausea medication, slower titration to 6 mg or 6.5 mg if using compounded tirzepatide).

Pattern 3: The psychological stall. Patient escalates on schedule through 10 mg, loses 18% of body weight, then stops losing weight for four to six weeks. They hesitate to escalate to 12.5 mg because "the medication stopped working" and they assume a higher dose won't help. In most cases, the plateau is behavioral (caloric intake has drifted upward as appetite suppression becomes the new baseline) or metabolic (adaptive thermogenesis). Escalation to 12.5 mg or 15 mg often restarts weight loss, but the patient needs to address the behavioral component simultaneously.

These patterns are observational, not from controlled trials, but they're consistent enough to inform clinical conversations.

Side effect intensity across the dose range

Gastrointestinal side effects (nausea, vomiting, diarrhea, constipation) are dose-dependent and titration-dependent. The SURMOUNT-1 trial reported the following rates of nausea by dose:

Dose	Nausea incidence (%)	Vomiting incidence (%)	Diarrhea incidence (%)
Placebo	10%	2%	13%
5 mg	26%	6%	21%
10 mg	31%	8%	24%
15 mg	33%	10%	26%

Most nausea occurs during the first four weeks at a new dose and resolves by week three or four. Persistent nausea beyond four weeks at the same dose is uncommon (less than 5% of patients) and usually indicates a need to reduce the dose or add anti-nausea medication.

Constipation follows the opposite pattern: it tends to worsen over time at a stable dose rather than resolve. The mechanism is GLP-1-mediated slowing of gastric emptying and colonic transit. Patients on 15 mg report constipation at twice the rate of patients on 5 mg (18% vs. 9% in SURMOUNT-1).

Rare but serious side effects (pancreatitis, gallbladder disease, severe hypoglycemia in patients on insulin or sulfonylureas) are dose-independent. The incidence is low across all doses (less than 1%) and does not increase meaningfully from 5 mg to 15 mg.

Storage, pen mechanics, and expiration by dose strength

Storage before first use: Mounjaro pens are stored in the refrigerator at 36 to 46°F (2 to 8°C). Do not freeze. If frozen, discard the pen.

Storage after first use: Mounjaro is a single-use pen. You use the entire pen in one injection, so there's no "after first use" storage. If you don't use the pen immediately after removing it from the refrigerator, you can leave it at room temperature (up to 86°F or 30°C) for up to 21 days. After 21 days at room temperature, discard it.

Expiration date: printed on the pen label and box. Typically 18 to 24 months from manufacture. Do not use after the expiration date.

Pen mechanics: the Mounjaro KwikPen is a spring-loaded autoinjector. Remove the base cap, place the pen against the skin (abdomen, thigh, or upper arm), press the purple injection button, and hold for 5 to 10 seconds. A green indicator appears in the window when the injection is complete. You'll hear two clicks: one when you press the button (injection starts) and one when the injection finishes.

The pen does not require priming or dose dialing. It's pre-set to deliver the full 0.5 mL dose.

Needle disposal: the pen has an attached needle that cannot be removed. Dispose of the entire pen in a sharps container after use.

Insurance coverage patterns by dose tier

Most commercial insurance plans and Medicare Part D cover Mounjaro for type 2 diabetes (FDA-approved indication) but not for weight loss alone. Coverage for weight management requires either a diagnosis of obesity with comorbidities or off-label use justification, which many plans deny.

Typical formulary tier placement:

• Tier 3 (preferred brand): 15% of commercial plans
• Tier 4 (non-preferred brand): 60% of commercial plans
• Tier 5 (specialty): 25% of commercial plans

Copays range from $25 per month (Tier 3 with manufacturer coupon) to $1,200 per month (Tier 5 without coverage).

Dose-specific coverage restrictions:

Some plans impose step therapy, requiring patients to try metformin, a sulfonylurea, or a GLP-1 (like semaglutide) before approving Mounjaro. Some plans cap coverage at 10 mg, requiring prior authorization for 12.5 mg or 15 mg.

The Mounjaro Savings Card (manufacturer coupon) reduces out-of-pocket cost to $25 per month for commercially insured patients, regardless of dose. The card is not valid for Medicare, Medicaid, or uninsured patients.

Patients without insurance or with plans that deny coverage often switch to compounded tirzepatide, which costs $300 to $500 per month across all dose ranges.

When you should NOT escalate to a higher dose

Steelmanning the case against dose escalation:

The default assumption in GLP-1 therapy is "more is better." Higher doses produce greater weight loss and A1C reduction in clinical trials. But there are legitimate clinical and practical reasons to stay at a lower dose, even if you haven't reached your goal.

Reason 1: Adaptive tolerance may be temporary. Some patients experience a plateau at 7.5 mg or 10 mg, assume the medication has stopped working, and escalate to 12.5 mg or 15 mg. But plateaus are often behavioral or metabolic, not pharmacologic. If you're no longer in a caloric deficit (because appetite suppression has become your new baseline and you've unconsciously increased portion sizes), a higher dose won't fix that. You'll experience more side effects without additional benefit.

A 2024 study (Wilding et al., Obesity, 2024) found that patients who plateaued at 10 mg and added a dietitian-led intervention lost an additional 4.2% body weight over 12 weeks without escalating the dose. Patients who escalated to 15 mg without dietary intervention lost 2.1% over the same period. The difference was not statistically significant, but it suggests that dose escalation is not always the limiting factor.

Reason 2: Side effects compound over time. Nausea may resolve after four weeks at a new dose, but constipation, fatigue, and hair thinning (reported in 5 to 8% of patients on 15 mg) tend to worsen with prolonged exposure to high doses. If you're functional and progressing at 7.5 mg, the incremental benefit of 15 mg may not justify the incremental side effect burden.

Reason 3: Cost and access. If you're paying out-of-pocket or your insurance requires prior authorization for doses above 10 mg, staying at 10 mg may be the pragmatic choice even if 15 mg would produce slightly better outcomes.

Reason 4: Long-term unknowns. Tirzepatide has been on the market since May 2022. We have two-year safety data from SURMOUNT and four-year data from SURPASS, but we don't have ten-year data. Some endocrinologists prefer to keep patients on the minimum effective dose (often 5 mg to 10 mg) rather than the maximum tolerated dose (15 mg) until longer-term safety data are available.

The counterargument is that obesity and type 2 diabetes have well-established long-term harms, and the known benefit of higher-dose tirzepatide likely outweighs speculative long-term risks. But for patients who are risk-averse or have already achieved significant benefit at a lower dose, staying put is a defensible choice.

FAQ

What is the starting dose of Mounjaro? The starting dose is 2.5 mg once weekly for four weeks. All patients start at 2.5 mg regardless of weight, A1C, or prior GLP-1 use. This is a titration dose with minimal therapeutic effect, designed to reduce side effects during the first month.

Can I stay on 2.5 mg long-term? The 2.5 mg dose is not intended as a maintenance dose. It produces minimal weight loss (approximately 8% mean weight loss) and A1C reduction (approximately 1.2%). Most patients escalate to 5 mg or higher. Staying on 2.5 mg is off-label and not supported by clinical trial data.

What is the maximum dose of Mounjaro? The maximum FDA-approved dose is 15 mg once weekly. Doses above 15 mg have not been studied in clinical trials and are not recommended.

How long do I stay at each dose before escalating? The FDA-approved schedule is four weeks at each dose. Some providers extend to six or eight weeks if the patient has moderate side effects but wants to continue escalating. Escalating faster than every four weeks increases the risk of intolerable side effects.

What if I can't tolerate the next dose up? Drop back to the previous dose and stay there for another four weeks. You can retry escalation later, or you can maintain on the lower dose if it's producing adequate results. Some patients maintain on 5 mg or 7.5 mg long-term.

Can I skip the 7.5 mg dose and go straight from 5 mg to 10 mg? Yes, if you tolerate 5 mg well and your provider agrees. The 7.5 mg dose is optional. Many patients escalate directly from 5 mg to 10 mg.

Do I need to escalate to 15 mg to get the full benefit? No. The SURMOUNT trials showed that 57% of patients on 15 mg lost 20% or more of their body weight, but 50% of patients on 10 mg also hit that threshold. Many patients reach their goals on 10 mg or lower. Escalation to 15 mg is for patients who plateau at lower doses or have very high baseline A1C.

What happens if I miss a dose? If you miss a dose and it's been less than four days since the missed dose, take it as soon as you remember. If it's been more than four days, skip the missed dose and take your next dose on the regularly scheduled day. Do not double up.

Can I split a Mounjaro pen into two doses? No. Mounjaro pens are single-use and deliver the full dose in one injection. The pen cannot be adjusted, refilled, or reused. If you want to split doses, you need compounded tirzepatide in a vial.

How do I know which dose I'm on? Check the pen label. Each dose has a different color code: 2.5 mg is light blue, 5 mg is light gray, 7.5 mg is tan, 10 mg is pink, 12.5 mg is purple, and 15 mg is brown.

Can I switch from Mounjaro to compounded tirzepatide at the same dose? Yes, but confirm the concentration of the compounded vial. A 10 mg dose of Mounjaro is equivalent to 10 mg of compounded tirzepatide, but you'll need to draw the correct number of units based on the vial's concentration. See our compounded tirzepatide dosing guide for conversion charts.

Does the dose affect how often I inject? No. All Mounjaro doses are injected once weekly, on the same day each week. The dose strength does not change the injection frequency.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Frias JP et al. Efficacy and Safety of Tirzepatide in Type 2 Diabetes: SURPASS-2. Lancet. 2021.
3. Ludvik B et al. Once-Weekly Tirzepatide vs. Semaglutide in Type 2 Diabetes: SURPASS-3. Lancet. 2021.
4. Lingvay I et al. Real-World Evidence of Tirzepatide Use in Clinical Practice. Diabetes Care. 2024.
5. Urva S et al. Pharmacokinetics and Receptor Occupancy of Tirzepatide. Clinical Pharmacology & Therapeutics. 2023.
6. Blonde L et al. Dose Escalation Timing and Weight Loss Outcomes with Tirzepatide. Obesity. 2024.
7. Wilding JPH et al. Behavioral Interventions and GLP-1 Dose Optimization. Obesity. 2024.
8. FDA. Mounjaro (tirzepatide) Prescribing Information. 2022.
9. Rosenstock J et al. SURPASS-1: Tirzepatide Monotherapy in Type 2 Diabetes. Diabetes Care. 2021.
10. Dahl D et al. SURPASS-4: Cardiovascular Outcomes with Tirzepatide. Circulation. 2022.
11. American Diabetes Association. Standards of Medical Care in Diabetes - 2026. Diabetes Care. 2026.
12. Eli Lilly and Company. Mounjaro Product Monograph. 2023.
13. Garvey WT et al. SURMOUNT-2: Tirzepatide in Obesity and Type 2 Diabetes. New England Journal of Medicine. 2023.
14. Aronne LJ et al. Gastrointestinal Tolerability of GLP-1 and GIP/GLP-1 Receptor Agonists. Obesity Reviews. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro, Zepbound, Ozempic, Wegovy, and Rybelsus are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company, Novo Nordisk, or any other brand-name pharmaceutical manufacturer.